Mirum Pharmaceuticals, Inc. Common Stock
MIRMMirum Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing therapies for rare and orphan diseases, particularly those affecting the liver. The company aims to address unmet medical needs through innovative and targeted treatments.
Company News
Eventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals in Q3, but the position's value increased by approximately $50.70 million to $184.92 million due to the stock's 89% surge over the past year. The share reduction appears to be portfolio management rather than a loss of confidence, as Mirum posted strong Q3 revenue growth of 47...
Mirum Pharmaceuticals has seen nearly 70% stock growth in 2025, with its flagship drug Livmarli driving sales and potential for continued expansion in 2026, supported by promising pipeline candidates volixibat and MRM-3379.
Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
